/PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody.
The Line Between Life and Death May Depend on Where You Live
Every state recognizes brain death, but the rules vary.
By Lola Butcher, Undark Fanatic Studio/Gary Waters/SCIENCE PHOTO LIBRARYGetty Images
Until Sept. 17, 2020, Sharon Frederick was an ostensibly healthy 63-year-old woman who spent her days caring for her disabled sister and going to church. That evening, she was praying the rosary over the telephone with a friend when she began slurring her words. By the time an ambulance delivered her to St. Elizabeth Medical Center in Utica, New York, Frederick was comatose after suffering a massive stroke.
Four days later, a physician declared her to be brain dead, and a death certificate was filed. Before she fell ill, however, Frederick had appointed two friends to act on her behalf if she were ever unable to make her own health care decisions. Her friends protested the diagnosis by filing a lawsuit that sought to void the death certificate and require the hospital t
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer’s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
BofA Securities 2021 Virtual Health Care Conference, May 13, 2021, at 8:45 AM ET
Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aß
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
Tuesday, May 11, 2021
Daubert motion to strike the plaintiff’s expert’s testimony regarding qEEG testing. In
Snyder v. ESURANCE Property and Casualty Insurance Company, Case No. 01-2018-CA-2651 (8
th Judicial Circ. Ala. Chua. Cty., FL), the defendant sought to bar the testimony of Dr. Lisa Avery, an eligible board neurologist, from testifying regarding her interpretation of a quantitative electroencephalogram (qEEG). To support its motion, the defendant submitted “only” three articles and argued at a hearing that using qEEG for diagnosing mild traumatic brain injury had been prohibited by the American Academy of Neurology (AAN) for over 20 years. Noteworthy in the court’s opinion was that the AAN guideline relied upon by the defense was “retired” in January 2020 and was no longer the official position of the Academy.